Authors: Anna Tarková 1,2,4; Kristína Ivkovičová 2; Zuzana Urbanová 2; Libor Hejsek 3,4; Jan Studnička 3,4,5 Authors place of work: Faculty Hospital with polyclinic Nové Zámky, Ophthalmology, department, Nové Zámky, Slovakia 1; Faculty Hospital in Nitra, Ophthalmology Department, Nitra, Slovakia 2; University Hospital Hradec Králové, Ophthalmology Department, Czech Republic 3; Charles University, Faculty of Medicine in Hradec Králové, Ophthalmology, Department, Czech Republic 4; VISUS, s. r. o., Police nad Metují, Czech Republic 5 Published in the journal: Čes. a slov. Oftal., 82, 2026, No. 3, p. 150-158 Category: Původní práce doi: https://doi.org/10.31348/2025/43
Aim: To evaluate changes in the subjective perception of visual acuity in everyday life during intravitreal ranibizumab treatment in patients with diabetic macular edema using the Slovak version of the international NEI VFQ-25 questionnaire.
Material and Methods: In a prospective study, 48 eyes of 30 treatment-naive patients were evaluated, and met the indication criteria. We determined best-corrected visual acuity in letter score (LS), intraocular pressure (IOP), central retinal thickness (CRT) and total macular volume (TMV). Patients received the NEI VFQ-25 questionnaire before the first and then after three, six and twelve months of treatment.
Results: Before treatment, LS averaged 68.1 letters, IOP 17.6 mmHg, CRT 480.5 μm, and TMV 11.2 mm3. After twelve months of intravitreal treatment, LS averaged 72.6 letters, IOP 17.0 mmHg, CRT 332.4 μm, and TMV 9.3 mm3. Comparison of data relating to subjective perception of vision before and after twelve months of treatment: perception of general health improved by 7%, vision in general improved by 15%, eye pain decreased by 8%, near vision improved by 12%, distance activities improved by 5%, social functioning improved by 4%, mental health improved by 6%, difficulties with functioning improved by 16%, dependency improved by 1%, driving improved by 2%, color vision improved by 7%, and peripheral vision improved by 9%.
Conclusion: We determined that anti-VEGF ranibizumab treatment improved objective parameters after one year of intravitreal therapy in LS, CRT and TMV. Subjective changes in visual perception improved in all the monitored parameters after one year of treatment.
diabetic macular edema – endothelial growth factor blockers – subjective changes in vision – ranibizumab (Lucentis)
1. Liew G, Michaelides M, Bunce C. A comparison of the causes of blindness certifications in England and Wales in working age adults (16-64 years), 1999-2000 with 2009-2010. BMJ Open. 2014 Feb 12;4(2):e004015. doi: 10.1136/bmjopen-2013-004015
2. Buch H, Vinding T, La Cour M, Appleyard M, Jensen GB, Nielsen NV. Prevalence and causes of visual impairment and blindness among 9980 Scandinavian adults: the Copenhagen City Eye Study. Ophthalmology. 2004 Jan;111(1):53-61. doi: 10.1016/j.ophtha.2003.05.010
3. Mangione CM, Lee PP, Pitts J, Gutierrez P, Berry S, Hays RD. Psychometric properties of the National Eye Institute Visual Function Questionnaire (NEI-VFQ). NEI-VFQ Field Test Investigators. Arch Ophthalmol. 1998 Nov;116(11):1496-1504. doi: 10.1001/archopht.116.11.1496
4. Mangione CM, Lee PP, Gutierrez PR, Spritzer K, Berry S, Hays RD. National Eye Institute Visual Function Questionnaire Field Test Investigators. Development of the 25-item National Eye Institute Visual Function Questionnaire. Arch Ophthalmol. 2001 Jul;119(7):1050 - 1058. doi: 10.1001/archopht.119.7.1050
5. Vodrážková E, Šefčiková S, Helbich M. Psychometrická validácia verzie “Dotazníka zrakových funkcií-25” v podmienkach Slovenska [Psychometric validation of visual function questionnaire (NEI VQF-25) under local conditions in Slovakia, E.U]. Cesk Slov Oftalmol. 2012 Jul;68(3):102-5, 107-108. Slovak.
6. Rees G, Sasongko MB, Fenwick EK, Nicolaou TE, Wong TY, Lamoureux EL. Impact of diabetic retinopathy on patients’ beliefs about diabetes. Clin Exp Optom. 2012 May;95(3):371-376. doi: 10.1111/ j.1444-0938.2012.00745
7. Trento M, Passera P, Trevisan M, et. al. Quality of life, impaired vision and social role in people with diabetes: a multicenter observational study. Acta Diabetol. 2013 Dec;50(6):873-877. doi: 10.1007/ s00592-013-0470-1
8. Granström T, Forsman H, Leksell J, Jani S, Raghib AM, Granstam E. Visual functioning and health-related quality of life in diabetic patients about to undergo anti-vascular endothelial growth factor treatment for sight-threatening macular edema. J Diabetes Complications. 2015 Nov-Dec;29(8):1183-1190. doi: 10.1016/j.jdiacomp.2015.07.026
9. Finger RP, Fenwick E, Marella M, et. al. The impact of vision impairment on vision-specific quality of life in Germany. Invest Ophthalmol Vis Sci. 2011 Jun 1;52(6):3613-3619. doi: 10.1167/ iovs.10-7127
10. Early Treatment Diabetic Retinopathy Study design and baseline patient characteristics. ETDRS report number 7. Ophthalmology. 1991 May;98(5 Suppl):741-756. doi: 10.1016/s0161 - 6420(13)38009-9
11. Kolář P, Lipková B, Štefaničková J. Štandardné postupy Názov: Liečba diabetického edému makuly (DEM) anti-VEGF liečbou v režime Treat and Extend platné od 1 júla 2022. [Internet; cited February 2025]. Available from: https://www.health.gov.sk/?Standardne-Postupy-V-Zdravotnictve
12. Anonym, 1. VFQ-25 manual (PDF). [Internet; cited February 2025]. Available from: https://www.rand.org/health-care/surveys_tools/ vfq.html
13. Daldal H, Turkyilmaz M, Balikoglu Yilmaz M, Berberoglu U. The Effect of Ranibizumab Loading Treatment on Vision-Related Quality of Life in Diabetic Macular Edema. Clin Pract. 2021 Sep 14;11(3):659-670. doi: 10.3390/clinpract11030081
14. Klein R, Klein BE, Moss SE. Visual impairment in diabetes. Ophthalmology. 1984 Jan;91(1):1-9.
15. Stein JD. Disparities between ophthalmologists and their patients in estimating quality of life. Curr Opin Ophthalmol. 2004 Jun;15(3):238-243. doi: 10.1097/01.icu.0000120712.35941.ad
Nemáte účet? Registrujte sa
Zadajte e-mailovú adresu, s ktorou ste vytvárali účet. Budú Vám na ňu zasielané informácie k nastaveniu nového hesla.
